Abstract: A novel family of primate CSF-1-like polypeptides is provided via recombinant techniques, including compositions and methods for their production and use.
Abstract: The use of interleukin-12 to prevent, to ameliorate, and to treat graft-versus-host disease in a mammal in need of such treatment is disclosed.
Type:
Grant
Filed:
January 21, 1994
Date of Patent:
November 12, 1996
Assignees:
Genetics Institute, Inc., The General Hospital Corporation
Abstract: Provided are porcine factor VIII nucleotide sequences and hybrid sequences encoding human/porcine chimeric factor VIII-type procoagulant proteins. DNAs encoding such chimeric factor VIII-type procoagulant proteins, pharmaceutical compositions containing such chimeric factor VIII-type procoagulant proteins, and methods of treating hemophilia using such chimeric factor VIII-type procoagulant proteins are also provided.
Type:
Grant
Filed:
September 14, 1993
Date of Patent:
October 8, 1996
Assignee:
Genetics Institute, Inc.
Inventors:
Debra Pittman, Alnawaz Rehemtulla, John M. Wozney, Randal J. Kaufman
Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A.sub.2 /B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Abstract: Purified BMP-5 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
September 7, 1993
Date of Patent:
August 6, 1996
Assignee:
Genetics Institute, Inc.
Inventors:
John M. Wozney, Vicki A. Rosen, Elizabeth A. Wang
Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of gestational hypertension or preeclampsia. The methods involve measuring serum M-CSF levels, and administration of M-CSF.
Type:
Grant
Filed:
March 10, 1994
Date of Patent:
August 6, 1996
Assignees:
Genetics Institute, Inc., Virginia Polytechnic Institute and State Univ.
Abstract: A novel method of screening for novel secreted mammalian proteins is described in which mammalian secretory leader sequences are detected using the yeast invertase gene as a reporter system.
Abstract: The invention provides novel DNA and peptide sequences encoding a family of phospholipase A.sub.2 enzymes, with specific activities of approximately 20 .mu.mol/min/mg in the mixed micelle assay. These enzymes are useful in methods for detecting the anti-inflammatory potential of various chemical agents. The invention also details novel methods for determining such potential using the novel sequences, methods for making the novel peptides, and methods for developing new anti-inflammatory drugs.
Abstract: A formulation is disclosed comprising a pharmaceutically acceptable admixture of an osteogenic protein and a sponge of porous particulate polymer matrix. The sponge may be prepared by treating the porous particulate polymer matrix with a suitable fusing material such as ethanol and a surfactant such as a polysorbate.
Type:
Grant
Filed:
September 19, 1994
Date of Patent:
May 28, 1996
Assignee:
Genetics Institute, Inc.
Inventors:
Jane S. Tjia, Brian D. Kelley, Richard P. Northey, C. Michael Philbrook
Abstract: A process for increasing the yield of recombinant bone-inducing proteins of the BMP-2 family is provided, wherein dextran sulfate is added to the culture medium in which cells expressing the proteins are grown.
Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A.sub.2 /B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Abstract: A method for reducing damage or depletion of gut epithelial cells (e.g., as a result of radiation therapy or chemotherapy) by administration of one or more of the following cytokines: interleukin 11 (IL-11), interleukin 6 (IL-6), leukemia inhibitory factor/cholinergic differentiation factor (LIF/CDF), oncostatin M (OSM), or ciliary neurotrophic factor (CNTF).
Abstract: Compositions and methods are provided for endopeptidase production and for enhanced efficiencies of processing heterologous precursor polypeptides to mature polypeptides, including proteins requiring gamma-carboxylation for biological activity. These compositions and methods utilize recombinant PACE, a mammalian endopeptidase that is specific for dibasic amino acid sites.
Type:
Grant
Filed:
May 20, 1992
Date of Patent:
October 24, 1995
Assignees:
Genetics Institute, Inc., Chiron Corporation
Inventors:
Philip J. Barr, Anthony J. Brake, Randal J. Kaufman, Louise Wasley, Patricia Tekamp-Olson, Polly A. Wong
Abstract: Purified BMP-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
May 27, 1994
Date of Patent:
October 17, 1995
Assignee:
Genetics Institute, Inc.
Inventors:
John M. Wozney, Elizabeth A. Wang, Vicki A. Rosen, Anthony J. Celeste
Abstract: A novel homogeneous human cytokine, Natural Killer Stimulatory Factor, having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing it.
Type:
Grant
Filed:
September 18, 1990
Date of Patent:
October 10, 1995
Assignee:
Genetics Institute, Inc.
Inventors:
Giorgio Trinchieri, Bice Perussia, Michiko Kobayashi, Steven C. Clark, Gordon G. Wong, Rodney Hewick
Abstract: This invention relates to recombinant Factor VIII:c variants, methods to produce the variants and pharmaceutical compositions containing same. The variants of this invention are characterized by modification of one or more specific proteolytic cleavage sites encompassing the arginine residues at positions 226, 336, 562, 740, 776, 1313, 1648, or 1721. The variants possess similar procoagulant activity to that of human Factor VIII:c.
Type:
Grant
Filed:
December 9, 1986
Date of Patent:
September 19, 1995
Assignee:
Genetics Institute, Inc.
Inventors:
Randal J. Kaufman, Debra D. Pittman, John J. Toole, Jr.
Abstract: Methods of treating mammalian soft tissue injuries such as thermal and chemical burns, surgical incisions, ulcers, abrasions, skin grafts, and nervous tissue damage by administering a therapeutically effective amount of homogeneous K-fibroblast growth factor are provided. Also provided are methods of treating mammalian musculo-skeletal disorders such as bone grafts, bone fractures, ligament tears, cartilage tears, tendon tears, bursa inflammation and tendon inflammation by administering a therapeutically effective amount of homogeneous K-fibroblast growth factor. In accordance with the methods of the invention, homogeneous K-fibroblast growth factor may be administered to the mammal alone or in combination with other growth factors.
Type:
Grant
Filed:
June 12, 1992
Date of Patent:
July 4, 1995
Assignee:
Genetics Institute, Inc.
Inventors:
David T. Rogers, Neil M. Wolfman, Jasbir S. Seehra